Skip to content

Which of the following signs indicate toxicity from local anaesthetic agents?

3 min read

The incidence of Local Anesthetic Systemic Toxicity (LAST) is estimated to be between 0.27 and 2 per 1,000 nerve blocks. Recognizing which of the following signs indicate toxicity from local anaesthetic agents is critical for patient safety.

Quick Summary

Toxicity from local anaesthetic agents presents with specific neurological and cardiovascular signs. Early symptoms include metallic taste and perioral numbness, which can progress to seizures and cardiac arrest.

Key Points

  • Initial CNS Signs: Early toxicity includes perioral numbness, metallic taste, and tinnitus.

  • Major CNS Event: Seizures are the most common severe CNS symptom of LAST.

  • Cardiovascular Progression: CVS signs often follow CNS symptoms, progressing from hypertension/tachycardia to bradycardia and hypotension.

  • Atypical Presentations: Up to 40% of LAST cases can present atypically, with cardiovascular collapse without preceding CNS signs.

  • Critical Agent: Bupivacaine is associated with more severe cardiovascular toxicity.

  • Primary Treatment: Immediate management includes stopping the injection, airway management, and 20% intravenous lipid emulsion therapy.

  • Prevention is Key: Using ultrasound, incremental injections, and the lowest effective dose can reduce LAST risk.

In This Article

Understanding Local Anesthetic Systemic Toxicity (LAST)

Local Anesthetic Systemic Toxicity (LAST) occurs when a local anesthetic reaches toxic levels in the bloodstream, a rare but life-threatening event. Causes include accidental intravascular injection, excessive dosage, or rapid absorption. High systemic levels of local anesthetics, which normally block nerve signals, can disrupt the central nervous system (CNS) and cardiovascular system (CVS). Recognizing and managing LAST promptly is crucial to prevent severe outcomes like cardiac arrest.

Central Nervous System (CNS) Signs of Toxicity

The CNS often shows the first signs of local anesthetic toxicity, particularly in awake patients. Symptoms typically progress from initial excitation to depression.

Early/Excitatory CNS Symptoms

These initial signs warn of rising toxic levels:

  • Perioral numbness and tongue paresthesia: Tingling or numbness around the mouth and on the tongue.
  • Metallic taste: A distinct metallic taste in the mouth.
  • Auditory and visual disturbances: Tinnitus, blurred or double vision.
  • Agitation and restlessness: Confusion, nervousness, or a feeling of impending doom.
  • Slurred speech (Dysarthria): Difficulty speaking clearly.
  • Muscle twitching: Involuntary twitches, especially in the face and extremities.

Late/Depressive CNS Symptoms

If unmanaged, the excitatory phase leads to CNS depression:

  • Seizures: Generalized tonic-clonic seizures are the most common major symptom, occurring in 60-70% of cases.
  • Drowsiness and loss of consciousness: Increasing drowsiness leading to unconsciousness or coma.
  • Respiratory depression and arrest: Deepening CNS depression can suppress breathing.

Cardiovascular System (CVS) Signs of Toxicity

Cardiovascular signs typically require higher blood concentrations of the anesthetic than CNS signs, though they can appear first or simultaneously, especially with potent agents like bupivacaine. Atypical presentations with cardiovascular symptoms but no prior CNS signs occur in about 20-40% of cases.

Early CVS Symptoms

Initial cardiovascular signs can be excitatory:

  • Hypertension: An initial increase in blood pressure.
  • Tachycardia: Increased heart rate.
  • Ventricular Arrhythmias: Irregular heart rhythms.

Late CVS Symptoms

This phase is often followed by profound cardiovascular depression:

  • Hypotension: A significant drop in blood pressure.
  • Bradycardia: A significantly slowed heart rate.
  • Conduction Blocks: Disrupted electrical signaling in the heart.
  • Cardiac Arrest: In severe cases, cardiovascular collapse occurs.

Comparison of CNS vs. Cardiovascular Signs

Feature Central Nervous System (CNS) Signs Cardiovascular System (CVS) Signs
Onset Often appear first, at lower drug concentrations Typically appear at higher drug concentrations, but can be the first sign (especially with bupivacaine)
Early Symptoms Perioral numbness, metallic taste, tinnitus, agitation, muscle twitching Hypertension, tachycardia, ventricular ectopy
Severe Symptoms Seizures, coma, respiratory arrest Profound hypotension, bradycardia, conduction blocks, asystole, cardiac arrest
Primary Agent More common with less potent agents like lidocaine More severe and common with highly lipophilic agents like bupivacaine

Management and Prevention

If LAST is suspected, immediately stop the anesthetic injection and call for help. Management involves airway support, seizure control with benzodiazepines, and cardiovascular support. The primary treatment for severe LAST is intravenous 20% lipid emulsion solution, which acts as a "lipid sink" to sequester anesthetic molecules.

Prevention is crucial and includes:

  • Using the lowest effective dose.
  • Injecting incrementally (3-5 mL) with aspiration.
  • Using ultrasound guidance.
  • Using an intravascular marker like epinephrine.
  • Monitoring the patient for at least 30 minutes post-injection.

Authoritative Link: The American Society of Regional Anesthesia and Pain Medicine (ASRA) provides a comprehensive checklist for managing LAST.

Conclusion

Recognizing the signs of toxicity from local anaesthetic agents is vital for healthcare providers. Symptoms range from subtle sensory changes to seizures and cardiac arrest. The classic presentation is a biphasic response starting with CNS excitation followed by depression and cardiovascular collapse. However, atypical presentations are common, requiring high vigilance. Understanding risk factors, employing preventative techniques, and being prepared to manage LAST with airway support and lipid emulsion therapy significantly improve patient outcomes.

Frequently Asked Questions

Early CNS signs can include perioral numbness, a metallic taste, and tinnitus.

Yes, LAST can occur from topical application, especially on large areas or broken skin, leading to systemic absorption.

Severe LAST, particularly with cardiac instability, is treated with intravenous 20% lipid emulsion solution to act as a 'lipid sink'.

Symptoms can appear within one minute of intravascular injection or be delayed over 30-60 minutes with slow absorption.

Bupivacaine is more cardiotoxic and can cause severe cardiovascular complications, sometimes without early CNS signs.

No. While seizures are the most common major sign, LAST can occur without them. Some patients may present directly with cardiovascular collapse.

Prevention includes using the lowest effective dose, incremental injections with aspiration, and ultrasound guidance.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.